HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Monograph Process Not Broken But Needs Repair – CHPA

This article was originally published in The Tan Sheet

Executive Summary

The trade group’s presentation at FDA’s upcoming public hearing will underscore the monograph process’s value in making more OTC drugs available but also ask why the process is not working as intended. Scheduled speakers also include Peter Barton Hutt, the former FDA chief counsel recognized as the architect of the monograph system, and self-care medication expert Bill Soller.

You may also be interested in...

Funding Doubles Women’s Health Firm Perelel’s Support, Boosts Odyssey Elixir Energy Visibility

Perelel doubles its support and makes $10m pledge to women’s health research groups; Odyssey Wellness starts boosting brand visibility for energy drinks with lion’s mane and cordyceps mushrooms.

Former FDA Deputy Commissioner Autor Leads Regulatory Affairs Consultancy

Deborah Autor will build on Healthcare Innovation Catalysts’ cross-functional technical expertise, furthering its role as an advisor in the private and public sectors as its first CEO.

BrainMD Latest To Target GLP-1 Secretion, AllerPops Promotes Prebiotics As Allergy Remedy

Line extension for physician’s brand BrainMD intends to support secretion of glucagon-like peptide-1; research shows AllerPops prebiotic lozenges improved rhinitis allergy symptoms significantly; and Nutramax Laboratories developing Practitioner Formulas supplements with health care professionals.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts